EyePoint Pharmaceuticals share price logo

EyePoint Pharmaceuticals

NASDAQ: EYPT

Small Cap

$4.25

+0.02

(+0.47%)

as on

EyePoint Pharmaceuticals Stock Performance

as on September 15, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $4.16
    $4.34
    downward going graph

    2.12%

    Downside

    2.12%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $3.95
    $19.11
    downward going graph

    7.06%

    Downside

    349.65%

    Upside

    downward going graph

EyePoint Pharmaceuticals share price movements today

Previous Close
$4.23
Open
$4.29
Volume
1.9M
Market Cap
$354.6M
Day's Low - High
$4.16 - $4.34
52 Week Low - High
$3.95 - $19.11

EyePoint Pharmaceuticals Historical Returns

1 Month Return
-71.19 %
3 Month Return
-64.82 %
1 Year Return
-68.31 %
3 Year Return
-59.45 %
5 Year Return
-57.84 %

EyePoint Pharmaceuticals Stock Fundamentals & Key Indicators

Check EyePoint Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$354.6M

EPS (TTM)

-3.74

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.14

Industry PE ratio

-6.33

PEG Ratio

0.03704780938813699

EBITDA

-294.4M

Revenue (TTM)

2.8M

Profit Margin

41.77%

Return On Equity TTM

-135.81%

EyePoint Pharmaceuticals Stock Valuation

Track how EyePoint Pharmaceuticals P/E has moved over time to understand its valuation trends.

EyePoint Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (-12.38x)

December 31, 2023

Industry (-6.33x)

December 31, 2025

Today (-5.76x)

December 31, 2025

Highest (-1.28x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -5.76x

EyePoint Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of EyePoint Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$354.6M-57.84%-1.1441.77%NA
BUY$44.6B614.61%NA0.00%NA
BUY$130.6B175.08%29.7686.04%NA
BUY$57.5B-66.24%-18.04-12.57%NA
BUY$80.5B21.74%18.9584.86%47.339999999999996%

Stock Returns calculator for EyePoint Pharmaceuticals Stock including INR - Dollar returns

The EyePoint Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

EyePoint Pharmaceuticals investment value today

Current value as on today

₹34,361

Returns

-₹65,639

(-65.64%)

Returns from EyePoint Pharmaceuticals Stock

-₹68,307 (-68.31%)

Dollar Impact

₹2,668 (+2.67%)

Analyst Recommendation on EyePoint Pharmaceuticals Stock

Based on 13 analysts

BUY

53.85%

Buy

46.15%

Hold

0.00%

Sell

Based on 13 analysts, 53.84615384615385% of analysts recommend a 'BUY' rating for EyePoint Pharmaceuticals. Average target price of $25.91

EyePoint Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on EyePoint Pharmaceuticals.

What analysts predicted

83.6%UPSIDE

Target Price

$25.91

Current Price

$4.25

Analyzed by

13 Analysts

Target

$25.91

EyePoint Pharmaceuticals target price $25.91, a slight upside of 83.6% compared to current price of $4.25. According to 13 analysts rating.

Indian Investors' Interest in EyePoint Pharmaceuticals Stock

Investment in EyePoint Pharmaceuticals Shares on INDmoney has grown by 3310.00% in the last 30 days, indicating increased investment activity.

Time period: to

Change:3310.00% versus previous 30 day period

Search interest for EyePoint Pharmaceuticals Stock has increased by 7191% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:7191% versus previous 30 day period

EyePoint Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
11
9
10
11
24
5
0
0
0
0
Gross Profit
10
8
9
10
23
5
0
0
0
0
Operating Income
-33
-34
-32
-45
-48
-62
-62
-70
-87
-97
EBITDA
-28
-30
-28
-40
-44
-58
-59
-57
-84
-93
Interest Expense
-
-
-
0
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
1
Income Before Tax
-29
-30
-29
-41
-45
-59
-59
-67
-84
-94
Income Tax Expense
-
-
-
0
-
0
-
0
0
-
Net Income
-29
-30
-29
-41
-45
-59
-59
-67
-84
-94
Net Profit Margin
93.50%
85.22%
93.01%
92.96%
96.71%
96.91%
25.36%
39.52%
24.14%
100.00%

EyePoint Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Jun 2017
Jun 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
2
5
20
34
36
41
46
43
31
Gross Profit
2
-13
17
28
28
33
41
39
29
Operating Income
-26
-49
-47
-37
-55
-99
-75
-145
-243
EBITDA
-51
-46
-48
-35
-50
-96
-69
-129
-229
Interest Expense
0
0
6
7
5
3
1
0
-
Depreciation
1
2
2
2
2
2
0
1
2
Income Before Tax
-53
-89
-56
-45
-58
-102
-70
-130
-231
Income Tax Expense
-
-
-
-
-
-
0
0
0
Net Income
-53
-53
-56
-45
-58
-102
-70
-130
-231
Net Profit Margin
100.00%
-524.86%
86.81%
83.09%
77.86%
79.89%
89.93%
91.42%
93.41%

EyePoint Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-29
-30
-29
-41
-45
-59
-59
-67
-84
-94
Operating Cash Flow
-31
-20
-39
-35
-53
-62
-59
-65
-80
-62
Investing Cash Flow
20
-160
16
-95
39
48
55
-74
59
75
Financing Cash Flow
0
0
11
151
0
0
7
166
-2
19
Change in Cash
-10
-180
-10
19
-14
-14
3
27
-24
32

EyePoint Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Jun 2017
Jun 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-18
-53
-56
-45
-58
-102
-70
-130
-231
Operating Cash Flow
-20
-21
-56
-14
-50
-65
1
-126
-240
Investing Cash Flow
-16
-16
0
0
-33
-17
-3
-219
68
Financing Cash Flow
8
29
33
37
216
0
187
164
173
Change in Cash
1
21
-23
22
133
-82
185
-181
2

Mutual Funds that own EyePoint Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in EyePoint Pharmaceuticals.

Funds
Holdings
Shares Held
Federated Hermes Equity Funds
5.5307%
4768135
VANGUARD INDEX FUNDS
4.026701%
3471505
Franklin Strategic Series
3.050899%
2630246
MUTUAL FUND SERIES TRUST
1.444788%
1245583
Fidelity Salem Street Trust
1.014838%
874914

Global Institutional Holdings in EyePoint Pharmaceuticals

Funds
Holdings
Vanguard
4.99%
iShares
4.32%
SPDR
1.28%
Dimensional
0.56%
Schwab
0.49%

Insights on EyePoint Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 28.0% return, outperforming this stock by 87.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 514.3% return, outperforming this stock by 582.6%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 696.0K → 507.0K (in $), with an average decrease of 27.2% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, EYPT stock has moved down by -71.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 8 quarters, -29.36M → -94.46M (in $), with an average decrease of 18.9% per quarter

About EyePoint Pharmaceuticals

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
OrganisationEyePoint Pharmaceuticals
Headquarters480 Pleasant Street, Watertown, MA, United States, 02472
IndustryBiotechnology
CEODr. Jay S. Duker M.D.
E-voting on sharesClick here to vote

Key Management of EyePoint Pharmaceuticals

Name

Title

Dr. Ramiro Ribeiro M.D., Ph.D.

Chief Medical Officer

Dr. Marcia Sellos-Moura Ph.D.

Chief Scientific Officer

Mr. Ron I. Honig Esq.

Chief Legal Officer & Company Secretary

Mr. David Scott Jones M.A.

Senior Vice President

Mr. Michael J. Maciocio

Chief Manufacturing Officer

Mr. Michael Campbell

Chief Commercial Officer

Dr. Jay S. Duker M.D.

President, CEO & Director

Mr. George O. Elston CPA

Executive VP & CFO

Ms. Jennifer Leonard

Chief People Officer & Senior VP of IT

Ms. Isabelle Lefebvre

Chief Regulatory Officer

FAQs

What is EyePoint Pharmaceuticals share price today?

EyePoint Pharmaceuticals share price today is $4.25 as on at the close of the market. EyePoint Pharmaceuticals share today touched a day high of $4.34 and a low of $4.16.

What is the 52 week high and 52 week low for EyePoint Pharmaceuticals share?

EyePoint Pharmaceuticals share touched a 52 week high of $19.11 on and a 52 week low of $3.95 on . EyePoint Pharmaceuticals stock price today i.e. is closed at $4.25,which is 77.76% down from its 52 week high and 7.59% up from its 52 week low.

What is EyePoint Pharmaceuticals's market capitalisation today?

EyePoint Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in EyePoint Pharmaceuticals Stock (EYPT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for EyePoint Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in EyePoint Pharmaceuticals Shares that will get you 0.3529 shares as per EyePoint Pharmaceuticals share price of $4.25 per share as on September 15, 2026 at 8:46 am IST.

What is the minimum amount required to buy EyePoint Pharmaceuticals Stock (EYPT) from India?

Indian investors can start investing in EyePoint Pharmaceuticals (EYPT) shares with as little as ₹95.54 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.40 in EyePoint Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on EyePoint Pharmaceuticals share’s latest price of $4.25 as on September 15, 2026 at 8:46 am IST, you will get 2.3529 shares of EyePoint Pharmaceuticals. Learn more about fractional shares .

What are the returns that EyePoint Pharmaceuticals has given to Indian investors in the last 5 years?

EyePoint Pharmaceuticals stock has given -57.84% share price returns and 29.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?